Alnylam Pharma (DUL) Stock Forecast & Price Target
DUL Analyst Ratings
Moderate Buy
17Buy8Hold0Sell
Based on 25 analysts giving stock ratings to Alnylam Pharma in the past 3 months
DUL Stock 12 Month Forecast
Average Price Target
EUR 285.13▲(98.63% Upside)Based on 25 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is EUR 285.13 with a high forecast of EUR 407.41 and a low forecast of EUR 196.99. The average price target represents a 98.63% change from the last price of EUR 143.55.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 407.41
AverageEUR 285.13
LowEUR 196.99
Highest Price TargetHighestEUR 407.41Average Price TargetEUR 285.13Lowest Price TargetLowestEUR 196.99
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | Barclays | EUR 402.93→EUR 340.25 | buy | 137.03%Upside | Reiterated | 11/02/26 | ||
| Danielle Brill | Truist Financial | EUR 282.05→EUR 201.46 | hold | 40.34%Upside | Downgraded | 11/02/26 | ||
| Whitney Ijem | Canaccord Genuity | EUR 384.13→EUR 289.21 | buy | 101.47%Upside | Reiterated | 11/02/26 | ||
| Patrick Trucchio | H.C. Wainwright | EUR 407.41 | buy | 183.81%Upside | Reiterated | 10/30/26 | ||
| Keay Nakae | Chardan Capital | EUR 380.54→EUR 335.77 | buy | 133.91%Upside | Reiterated | 10/30/26 | ||
| Martin Auster | Raymond James | EUR 376.07→EUR 282.05 | buy | 96.48%Upside | Reiterated | 10/30/26 | ||
| Edward Tenthoff | Piper Sandler | EUR 437.85→EUR 367.11 | buy | 155.74%Upside | Reiterated | 10/30/26 | ||
| Joon Lee | UBS | EUR 316.97→EUR 294.59 | buy | 105.21%Upside | Reiterated | 10/30/26 | ||
| William Pickering | Bernstein | ― | hold | ― | Downgraded | 10/30/26 | ||
| Salveen Richter | Goldman Sachs | EUR 479.93→EUR 286.53 | buy | 99.60%Upside | Reiterated | 10/30/26 | ||
| Michael Ulz | Morgan Stanley | EUR 268.62→EUR 214.90 | hold | 49.70%Upside | Assigned | 10/30/26 | ||
| Ritu Baral | TD Cowen | EUR 431.58→EUR 316.97 | buy | 120.81%Upside | Assigned | 10/30/26 | ||
| Ilya Zubkov | Freedom Capital Markets | EUR 367.11→EUR 313.39 | buy | 118.31%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 10/29/26 | ||
| Faisal Khurshid | Jefferies | EUR 232.80→EUR 223.85 | hold | 55.94%Upside | Reiterated | 10/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | 11/02/26 | EUR 402.93→EUR 340.25 | buy | 137.03%Upside | Reiterated | Barclays | ||
| Danielle Brill | 11/02/26 | EUR 282.05→EUR 201.46 | hold | 40.34%Upside | Downgraded | Truist Financial | ||
| Whitney Ijem | 11/02/26 | EUR 384.13→EUR 289.21 | buy | 101.47%Upside | Reiterated | Canaccord Genuity | ||
| Patrick Trucchio | 10/30/26 | EUR 407.41 | buy | 183.81%Upside | Reiterated | H.C. Wainwright | ||
| Keay Nakae | 10/30/26 | EUR 380.54→EUR 335.77 | buy | 133.91%Upside | Reiterated | Chardan Capital | ||
| Martin Auster | 10/30/26 | EUR 376.07→EUR 282.05 | buy | 96.48%Upside | Reiterated | Raymond James | ||
| Edward Tenthoff | 10/30/26 | EUR 437.85→EUR 367.11 | buy | 155.74%Upside | Reiterated | Piper Sandler | ||
| Joon Lee | 10/30/26 | EUR 316.97→EUR 294.59 | buy | 105.21%Upside | Reiterated | UBS | ||
| William Pickering | 10/30/26 | ― | hold | ― | Downgraded | Bernstein | ||
| Salveen Richter | 10/30/26 | EUR 479.93→EUR 286.53 | buy | 99.60%Upside | Reiterated | Goldman Sachs | ||
| Michael Ulz | 10/30/26 | EUR 268.62→EUR 214.90 | hold | 49.70%Upside | Assigned | Morgan Stanley | ||
| Ritu Baral | 10/30/26 | EUR 431.58→EUR 316.97 | buy | 120.81%Upside | Assigned | TD Cowen | ||
| Ilya Zubkov | 10/30/26 | EUR 367.11→EUR 313.39 | buy | 118.31%Upside | Reiterated | Freedom Capital Markets | ||
| Unknown AnalystNot Ranked | 10/29/26 | ― | hold | ― | Reiterated | Guggenheim | ||
| Faisal Khurshid | 10/29/26 | EUR 232.80→EUR 223.85 | hold | 55.94%Upside | Reiterated | Jefferies |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Alnylam Pharma
3 Months
Success Rate24/40 ratings generated profit
60%
Average Return
+5.33%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.33% per trade.
1 Year
Success Rate19/29 ratings generated profit
66%
Average Return
+18.62%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +18.62% per trade.
2 Years
Success Rate27/40 ratings generated profit
68%
Average Return
+27.51%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 67.50% of your transactions generating a profit, with an average return of +27.51% per trade.
DUL Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 34 | 35 | 29 | 27 | 21 |
| Buy | 19 | 23 | 24 | 20 | 10 |
| Hold | 10 | 9 | 9 | 14 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 63 | 67 | 62 | 61 | 44 |
In the current month, DUL has received 31 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 285.13.
DUL Financial Forecast
HighEUR 2.34
ConsensusEUR 1.54
LowEUR 0.51
DUL Earnings Forecast
Next quarter’s earnings estimate for DUL is EUR 1.54 with a range of EUR 0.51 to EUR 2.34. The previous quarter’s EPS was EUR 14.08. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 1.46B
ConsensusEUR 1.37B
LowEUR 1.3B
DUL Sales Forecast
Next quarter’s sales forecast for DUL is EUR 1.37B with a range of EUR 1.30B to EUR 1.46B. The previous quarter’s sales results were EUR 1.31B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
DUL Stock Forecast FAQ
What is DE:DUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharma’s 12-month average price target is €285.13.
What is DE:DUL’s upside potential, based on the analysts’ average price target?
Alnylam Pharma has 98.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharma a Buy, Sell or Hold?
Alnylam Pharma has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 8 hold ratings and 0 sell ratings.
What is Alnylam Pharma’s share price target?
The average share price target for Alnylam Pharma is €285.13. This is based on 25 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €407.41, and the lowest forecast is €196.99. The average share price target represents a 98.63% increase from the current price of €143.55.
What do analysts say about Alnylam Pharma?
Alnylam Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Street analysts.
How can I buy shares of Alnylam Pharma?
To buy shares of DE:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
